What question did this study set out to answer?

Assess the impact of subcutaneous tocilizumab therapy on patients with Castleman Disease.

May 7, 2026Journal of Paediatrics and Child Health0 citations

Effective Use of Subcutaneous Tocilizumab in a Case of Castleman Disease Progressing From Unicentric to Multicentric Form

SNSamuele Naviglio FNFrancesca Nicolardi RBRossana Bussani

Key Points

Assess the impact of subcutaneous tocilizumab therapy on patients with Castleman Disease.
Described a case of Castleman Disease progression from unicentric to multicentric form in a child.
Administered subcutaneous tocilizumab as a therapeutic intervention.
Monitored patient outcomes regarding quality of life and hospital admissions.
Subcutaneous tocilizumab therapy improved the patient's quality of life.
Reduced the frequency of hospital admissions previously required for intravenous infusions.

Abstract

New Findings Castleman Disease can progress from a unicentric to a multicentric form in children. Subcutaneous tocilizumab is a safe and effective therapy for patients with Castleman Disease, improving quality of life and eliminating the need for frequent hospital admissions for intravenous infusions.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Naviglio et al. (2026) studied this question.

synapsesocial.com/papers/69fbef68164b5133a91a3555 https://doi.org/10.1111/jpc.70404

Ask AI

Helpful

Bookmark

View Full Paper

May 7, 2026Journal of Paediatrics and Child Health0 citations

Effective Use of Subcutaneous Tocilizumab in a Case of Castleman Disease Progressing From Unicentric to Multicentric Form

View Full Paper

SNSamuele Naviglio FNFrancesca Nicolardi RBRossana Bussani

Key Points

Assess the impact of subcutaneous tocilizumab therapy on patients with Castleman Disease.
Described a case of Castleman Disease progression from unicentric to multicentric form in a child.
Administered subcutaneous tocilizumab as a therapeutic intervention.
Monitored patient outcomes regarding quality of life and hospital admissions.
Subcutaneous tocilizumab therapy improved the patient's quality of life.
Reduced the frequency of hospital admissions previously required for intravenous infusions.

Abstract

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Naviglio et al. (2026) studied this question.

synapsesocial.com/papers/69fbef68164b5133a91a3555 https://doi.org/10.1111/jpc.70404

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper